184 related articles for article (PubMed ID: 26833164)
1. Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.
Deng S; Pan W; Liao W; de Hoog GS; Gerrits van den Ende AH; Vitale RG; Rafati H; Ilkit M; Van der Lee AH; Rijs AJ; Verweij PE; Seyedmousavi S
Antimicrob Agents Chemother; 2016 Apr; 60(4):2346-51. PubMed ID: 26833164
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
Vitale RG; Afeltra J; de Hoog GS; Rijs AJ; Verweij PE
J Antimicrob Chemother; 2003 May; 51(5):1297-300. PubMed ID: 12697648
[TBL] [Abstract][Full Text] [Related]
3.
Samaddar A; Mendonsa JM; Sudhaharan S; S N; Kindo AJ; Shetty A; Pamidimukkala U
Microbiol Spectr; 2024 Jun; ():e0078124. PubMed ID: 38920376
[TBL] [Abstract][Full Text] [Related]
4. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
5. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Mar; 32(3):151-7. PubMed ID: 2733727
[TBL] [Abstract][Full Text] [Related]
6. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Jan; 32(1):46-52. PubMed ID: 2747742
[TBL] [Abstract][Full Text] [Related]
7. Post covid cerebral phaeohyphomycosis by Rhinocladiella mackenziei: An unusual association.
Khandhar AV; Warade A; Agrawal U; Shetty A; Sunavala A; Desai K
Indian J Med Microbiol; 2023; 46():100430. PubMed ID: 37945123
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of five antifungal agents against pathogenic Exophiala species.
Li D; Li R; Wang D; Ma S
Chin Med J (Engl); 1999 Jun; 112(6):484-8. PubMed ID: 11601322
[TBL] [Abstract][Full Text] [Related]
9. Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.
Deng S; Lei W; de Hoog GS; Yang L; Vitale RG; Rafati H; Seyedmousavi M; Tolooe A; van der Lee H; Liao W; Verweij PE; Seyedmousavi S
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581111
[TBL] [Abstract][Full Text] [Related]
10. Flucytosine analogues obtained through Biginelli reaction as efficient combinative antifungal agents.
Wani MY; Ahmad A; Kumar S; Sobral AJ
Microb Pathog; 2017 Apr; 105():57-62. PubMed ID: 28189732
[TBL] [Abstract][Full Text] [Related]
11. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.
Duarte AP; Pagnocca FC; Baron NC; Melhem Mde S; Palmeira GA; de Angelis Dde F; Attili-Angelis D
Mycopathologia; 2013 Jun; 175(5-6):455-61. PubMed ID: 23229615
[TBL] [Abstract][Full Text] [Related]
14. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
Soares BM; Santos DA; Kohler LM; da Costa César G; de Carvalho IR; dos Anjos Martins M; Cisalpino PS
Rev Iberoam Micol; 2008 Dec; 25(4):242-5. PubMed ID: 19071894
[TBL] [Abstract][Full Text] [Related]
15. Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei in Persian Gulf region: A case and review.
Mohammadi R; Mohammadi A; Ashtari F; Khorvash F; Hakamifard A; Vaezi A; Javidnia J; Meis JF; Badali H
Mycoses; 2018 Apr; 61(4):261-265. PubMed ID: 29205524
[TBL] [Abstract][Full Text] [Related]
16. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
Te Dorsthorst DT; Verweij PE; Meis JF; Punt NC; Mouton JW
Antimicrob Agents Chemother; 2004 Jun; 48(6):2007-13. PubMed ID: 15155192
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.
Barchiesi F; Spreghini E; Maracci M; Fothergill AW; Baldassarri I; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2004 Sep; 48(9):3317-22. PubMed ID: 15328091
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous phaeohyphomycosis of the sole caused by Exophiala jeanselmei and its susceptibility to amphotericin B, 5-FC and ketoconazole.
Hironaga M; Mochizuki T; Watanabe S
Mycopathologia; 1982 Aug; 79(2):101-4. PubMed ID: 6290889
[No Abstract] [Full Text] [Related]
19. Antifungal agents. Part I. Amphotericin B preparations and flucytosine.
Patel R
Mayo Clin Proc; 1998 Dec; 73(12):1205-25. PubMed ID: 9868423
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination.
Corrado ML; Kramer M; Cummings M; Eng RH
Sabouraudia; 1982 Jun; 20(2):109-13. PubMed ID: 6287653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
